Americas

As drug developers are increasingly prioritizing their later stage assets and bringing them through to approval, the Gene Therapy
Comparability Summit will unite large pharma and innovative biotechs to ensure you can establish comparability at every stage of development, supporting a seamless transition to the larger scales required for commercialization. Focused specifically on enhancing gene therapy comparability approaches, this event will ensure you can maintain safety, quality, consistency and efficacy while adapting manufacturing processes, methods and platforms, to ensure you satisfy regulatory demands and avoid costly delays to clinical programs.

Whether you are focusing on specific characterization methods, enhancing your genome sequencing, advancing your understanding of full and partial particles, or advancing your early-stage bioassays, with 4 tracks, 8 pre-conference workshops and a post-conference focus day, the 4th Gene Therapy Analytical Development Summit will encompass all aspects of analytical development, giving you the chance to address and overcome challenges. If you work in quality control, quality assurance, or process development – we’ve listened and we’ve answered. This year’s agenda includes a novel track designed for quality control and process development groups working in gene therapy. Talks include enhancing the knowledge transfer between departments, bridging between analytical methods with regards to QC/PD, and enhancing in-process development support. Whether you’re working with AAV, non-viral vectors or lentiviral vectors, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development.

Explore the latest advancements in phenotypic and target-based discovery, chemical biology as well as drug design at our two-day summit. The event will bring together leading experts in the fields of Organoid Discovery, Phenotypic Screening, Targeted Protein Degradation, AI Computational Drug Design and Lead Optimzation. A plethora of interactive panel and roundtable discussions, with ample networking opportunities to meet and discuss with world leading drug discovery experts.

As newly published data show the first Gamma Delta T cell therapy’s clinical efficacy in patients, the race to market for the first allogeneic and solid tumor-targeting γδT has begun. Join us at the 3rd Gamma Delta T Therapies Summit alongside 120+ of the world’s leaders in the field to discuss discovery to manufacturing and clinical development of these ‘holy grail’ therapies in allogeneic and solid tumor settings. Developed with key opinion leaders such as Adrian Hayday, and experts from Adicet Bio, Lava Therapeutics, IN8 Bio, and many more, attend this meeting to engage in interactive discussions and gain the actionable insights to advance bench to commercial bedside development of γδT-based therapies. Gather in person for the very first time with industry pioneers harnessing GDT cells to bring to market more cytotoxic, clinically safe therapies for solid tumors. From modulating cell activity through genetic engineering and antibody engagement to enhancing the functionality of GDT cells through an improved understanding of their intrinsic biology, this is a conversation you won’t want to miss.

Exploring the latest developments & research across biologics and small molecule formulation & drug delivery, new modalities formulation & delivery as well inhaled drug delivery. 2 events in one: 5th Annual Formulation & Drug Delivery USA Congress;
5th Annual Inhalation & Respiratory Drug Delivery USA Congress

From the earliest stages of characterization to the final steps of preparing for release and commercialization, our diverse program provides a comprehensive and unparalleled journey through end-to-end potency assay considerations. With a focus on practical insights, this summit equips you with the knowledge and expertise to ensure you’re prepared to excel in your role, which ultimately will bring better therapies to patients faster.

Biotech Showcase provides biotechnology companies, pharmaceutical executives and investors an opportunity to meet in one place during the world’s largest annual healthcare investor conference.

Over the past 10 years, CHI’s Immuno-Oncology Summit has become the leading annual meeting focusing on the latest applied research, providing comprehensive and in-depth coverage across all modalities and stages in the pipeline. Every year, we assemble an international mix of thought leaders and decision makers from industry and academia to bring you the latest developments in immuno-oncology, while providing access to a comprehensive 3-day program and extensive networking opportunities that CHI’s IO Summit provides.

Where the new wave of life science innovators partner to fuel the future of drug development.

We’ll examine challenges facing the industry with NEW case studies, NEW perspectives and NEW approaches. Learn from industry, academia and the FDA at 3 Conference Programs, Symposium, Training Seminar, Workshop and 5 Short Courses. Once again, we’ll host interactive breakouts on various niche topics so delegates can share experiences and generate new ideas.